Cortechs.ai | A word from the CEO: 2015 in review

A word from the CEO: 2015 in review

NeuroQuant_2015_infographic1.png2015 was an incredible year for Cortechs.ai, with the team continuing to build on the momentum we started in 2014. During the year, we experienced remarkable growth in our business, added many significant new customers and expanded our strategic business partnerships.

With over 100,000 brains analyzed using NeuroQuant, it is exciting to watch the growth indicating an increased acceptance and realized importance of using quantitative imaging for the assessment of neurological disorders. During 2015, we established NeuroQuant as the most proven and most accurate quantitative imaging solutions and enjoyed worldwide support within hospitals, universities, radiology centers, clinical and research practices and military hospitals. These facilities see and understand the value of NeuroQuant’s volumetric measurements of subcortical structures aiding in the assessment of a variety of clinical disciplines, from dementia, through epilepsy, multiple sclerosis, traumatic brain injuries and brain development.

In the middle of 2015 we released NeuroQuant 2.0, providing significant additions and improvements, among them, new and improved output reports for ages 3 years to 100, the advanced Dynamic Atlas™ segmentation and registration technology, increased accuracy and precision of brain segmentation, and operating system independence. Toward the end of 2015, we expanded NeuroQuant 2.0 to include productivity enhancing capabilities such as the use of parallel imaging on GE, Philips and Siemens 3.0 T scanners, providing faster scan times, the addition of Toshiba Titan 3T scanner compatibility and PowerScribe 360 integration. Click on the infographic to the right to see a better overall picture of 2015’s developments

With these expanded capabilities NeuroQuant continues to be the paramount solution for the assessment of neurological conditions. From brain development to Alzheimer’s, multiple sclerosis, epilepsy and brain trauma, NeuroQuant helps enhance the quality of patient care. As always, we welcome feedback and ideas for improvement from anybody that wants to share it with us.

2015 was a great year, and we are thrilled to see what unfolds for 2016. Stay tuned – more exciting developments are happening and we look forward to sharing them with you!

Guri Stark, CEO
Cortechs.ai

More Resources

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.

07/28/2025

Longitudinal Assessment of Traumatic Brain Injury Using NeuroQuant®

A case study with Dr. Suzie Bash on NeuroQuant as a reliable, reimbursable, and efficient tool in the evaluation and follow-up of TBI.

07/24/2025

Understanding the Hippocampal Occupancy Score

One of the most frequently asked questions among customers is, “What does the Hippocampal Occupancy Score (HOC) represent within the Dementia Report?”

07/16/2025

Advancing Prostate MRI with Restriction Spectrum Imaging

Why is OnQ Prostate unique, and what makes it a game-changer for clinicians?

07/08/2025

Enhancing Neuroimaging Insights: LVV & ICV Quantification and Midline Shift Indexing with NeuroAlign CT

Time-sensitive and precise diagnostic imaging can mean the difference between rapid intervention and devastating outcomes.

07/07/2025

When to repeat an MRI scan for NeuroQuant®

NeuroQuant® can process an array of exams. However, there are some circumstances that will require you to repeat a scan.
Scroll to Top